Spyre Therapeutics, Inc.NASDAQ: SYRE

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

· Issued by Spyre Therapeutics, Inc.

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p